Analyst Price Target is $14.00
▲ +530.63% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Immix Biopharma in the last 3 months. The average price target is $14.00, with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 530.63% upside from the last price of $2.22.
Current Consensus is
Buy
The current consensus among 1 polled investment analysts is to buy stock in Immix Biopharma. This Buy consensus rating has held steady for over two years.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Read More